Press Release Details

Cerus Appoints North American Sales Team Leadership


CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ: CERS) announced today the appointments of Kenneth Trader as vice president, sales, North America, and Scott Buker as senior director, North American market development. Both will join the company in January 2014. Mr. Trader will be responsible for sales operations in North America, including planning for anticipated product launches as well as establishing and building the sales team responsible for product adoption. Mr. Buker will be responsible for key launch activities and for management of national accounts in North America.

Mr. Trader comes to Cerus with twenty-five years of leadership experience in sales and marketing management, having served most recently as vice president, sales and payer relations at US Bioservices, a division of AmerisourceBergen Specialty Group. Prior to this role, Mr. Trader served as vice president, corporate business development at AmerisourceBergen Specialty Group. He has also previously held the roles of vice president of sales and marketing, hemophilia health services with Accredo Health Group, and director of national sales with Baxter BioScience, a division of Baxter Healthcare Corporation. Throughout his career, Mr. Trader has consistently demonstrated success in numerous biologic product launches and in building out commercial organizations. Mr. Trader has served on the National Hemophilia Foundation's board of directors since 2010, and currently holds the position of vice chair.

“We are delighted to welcome Ken to the Cerus team at such an exciting time in the company’s history,” said William ‘Obi’ Greenman, Cerus’ chief executive officer and president. “As we continue working to advance the INTERCEPT Blood System in both the U.S. and Canada, Ken will immediately play a significant leadership role in our ongoing launch preparations for North America, given his depth of industry knowledge and experience.”

Mr. Buker joins Cerus with over thirty years of sales and marketing experience in the blood testing and processing industry. He most recently served as executive director, strategic accounts, for Biomedical Services at the American Red Cross. Prior to this role, Mr. Buker served as senior director, corporate accounts, and director, national accounts, also at the Red Cross. Before joining the American Red Cross, he held leadership roles in sales and marketing at Whatman plc, Johnson & Johnson, E.I. DuPont de Nemours, and Abbott Laboratories.

“Scott brings a wealth of experience to our North American sales leadership team,” said Mr. Greenman. “His extensive understanding of the U.S. blood banking industry and his past successes in establishing and managing national hospital accounts will be key to our launch planning and execution efforts.”


Cerus Corporation is a biomedical products company focused in the field of blood safety. In in vitro studies, the company’s INTERCEPT Blood System has been demonstrated to inactivate a broad range of viruses, bacteria and parasites that may be present in donated blood, including established threats such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. In the United States, Cerus is seeking regulatory approval of the INTERCEPT Blood System for plasma and platelets. The INTERCEPT red blood cell system is in clinical development. See for more information.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

This press release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements relating to the potential regulatory approval and commercial launch of the INTERCEPT Blood System in the United States and other North American countries, including the timing thereof, and customer adoption of the INTERCEPT Blood System in the United States and other North American countries. These forward-looking statements are based upon Cerus’ current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, the risk that Cerus may encounter unanticipated difficulties complying with the prescribed submission timing or other modular Premarket Approval application requirements of FDA, or complying with other regulatory requirements for product approval in the U.S. or other North American countries and the risk that customers may not adopt the INTERCEPT Blood System in the U.S. or other North American countries, as well as other risks detailed in Cerus' filings with the Securities and Exchange Commission (SEC), including in Cerus' quarterly report on Form 10-Q for the quarter ended September 30, 2013, filed with the SEC on November 1, 2013. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Cerus does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.

Source: Cerus Corporation

Cerus Corporation

Lainie Corten, 925-288-6319

Sr Director, Global Marketing & Investor Relations

  • Global Headquarters

  • 2550 Stanwell Drive
    Concord, CA US 94520
    +1 925.288.6000
  • European Headquarters

  • Stationsstraat 79-D
    3811 MH Amersfoort, Netherlands
    +31 (0) 33 49 60 600